aspirin has been researched along with Abnormalities, Congenital in 17 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Excerpt | Relevance | Reference |
---|---|---|
"The purpose of this study was to determine, on the basis of published reports, whether aspirin use during the first trimester of pregnancy is associated with an increased risk of congenital malformations." | 8.81 | Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. ( Boskovic, R; Costei, A; Koren, G; Kozer, E; Nikfar, S; Nulman, I, 2002) |
"The purpose of this study was to determine, on the basis of published reports, whether aspirin use during the first trimester of pregnancy is associated with an increased risk of congenital malformations." | 4.81 | Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. ( Boskovic, R; Costei, A; Koren, G; Kozer, E; Nikfar, S; Nulman, I, 2002) |
"Today, pregnancy is no longer considered impossible in women with lupus." | 2.53 | Pregnancy in women with systemic lupus erythematosus (SLE). ( Moroni, G; Ponticelli, C, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 6 (35.29) | 18.7374 |
1990's | 3 (17.65) | 18.2507 |
2000's | 3 (17.65) | 29.6817 |
2010's | 5 (29.41) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bloor, M | 1 |
Paech, M | 1 |
Moroni, G | 1 |
Ponticelli, C | 1 |
Kristensen, DM | 1 |
Mazaud-Guittot, S | 1 |
Gaudriault, P | 1 |
Lesné, L | 1 |
Serrano, T | 1 |
Main, KM | 1 |
Jégou, B | 1 |
Luk, YS | 1 |
Man, EM | 1 |
Sy, AN | 1 |
Capone, C | 1 |
Burjonrappa, S | 1 |
Kozer, E | 1 |
Nikfar, S | 1 |
Costei, A | 1 |
Boskovic, R | 1 |
Nulman, I | 1 |
Koren, G | 1 |
HARLEY, JD | 1 |
Bonaminio, PN | 1 |
de Regnier, R | 1 |
Chang, E | 1 |
Day, N | 1 |
Manzi, S | 1 |
Ramsey-Goldman, R | 1 |
Vroom, F | 1 |
van den Berg, PB | 1 |
de Jong-van den Berg, LT | 1 |
Tunbridge, RD | 1 |
Coulam, CB | 1 |
Tiboni, GM | 1 |
Iammarrone, E | 1 |
Piccirillo, G | 1 |
Liberati, M | 1 |
Bellati, U | 1 |
Shepard, TH | 1 |
Wilson, JG | 1 |
Gavan, JA | 1 |
Nielsen, FH | 1 |
Sunde, ML | 1 |
Hoekstra, WG | 1 |
Palmer, AK | 1 |
Warkany, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Copenhagen Analgesic Study[NCT04369222] | 600 participants (Anticipated) | Observational | 2020-03-01 | Recruiting | |||
Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension: A Pilot Study[NCT04908982] | Phase 4 | 60 participants (Anticipated) | Interventional | 2021-05-28 | Recruiting | ||
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 189 |
Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 1078 |
Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 78 |
Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 303 |
Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 134 |
Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 141 |
Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 42 |
Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 352 |
Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 264 |
Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 668 |
Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 1506 |
Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 214 |
Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 26 |
Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 54 |
Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 9 |
Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 23 |
Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 290 |
Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 8 |
Placebo Arm | 21 |
5 reviews available for aspirin and Abnormalities, Congenital
Article | Year |
---|---|
Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation.
Topics: Abortion, Habitual; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiphospholipid Syndrome; Aspir | 2013 |
Pregnancy in women with systemic lupus erythematosus (SLE).
Topics: Abortion, Spontaneous; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspi | 2016 |
Analgesic use - prevalence, biomonitoring and endocrine and reproductive effects.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Commerce; | 2016 |
Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis.
Topics: Abnormalities, Drug-Induced; Aspirin; Case-Control Studies; Cohort Studies; Congenital Abnormalities | 2002 |
Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis.
Topics: Abnormalities, Drug-Induced; Aspirin; Case-Control Studies; Cohort Studies; Congenital Abnormalities | 2002 |
Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis.
Topics: Abnormalities, Drug-Induced; Aspirin; Case-Control Studies; Cohort Studies; Congenital Abnormalities | 2002 |
Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis.
Topics: Abnormalities, Drug-Induced; Aspirin; Case-Control Studies; Cohort Studies; Congenital Abnormalities | 2002 |
The management of pregnancy in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Aspirin; Blood Pressure; Congenital Abnormalities; Female; Humans; H | 1994 |
12 other studies available for aspirin and Abnormalities, Congenital
Article | Year |
---|---|
Bilateral hypoplasia of the internal carotid arteries.
Topics: Angiography; Aspirin; Carotid Artery, Internal; Congenital Abnormalities; Humans; Imaging, Three-Dim | 2010 |
Congenital spine deformities: a new screening indication for blunt cerebrovascular injuries after cervical trauma?
Topics: Anticoagulants; Aspirin; Carotid Artery, Internal, Dissection; Cerebral Angiography; Cervical Atlas; | 2010 |
GROSS CONGENITAL MALFORMATIONS IN SIBLINGS OF CHILDREN WITH GLUCOSE-6-PHOSPHATE DEHYDROGENASE-DEFICIENT ERYTHROCYTES.
Topics: Abnormalities, Drug-Induced; Aspirin; Congenital Abnormalities; Erythrocytes; Glucosephosphate Dehyd | 1964 |
Minor physical anomalies are not increased in the offspring of mothers with systemic lupus erythematosus.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Congenital Abnormalities; Fe | 2006 |
Prescribing of NSAIDs and ASA during pregnancy; do we need to be more careful?
Topics: Abortion, Spontaneous; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Congenit | 2008 |
Hypothesis: antiphospholipid antibodies associated with congenital anomalies?
Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Congeni | 1997 |
Aspirin pretreatment potentiates hyperthermia-induced teratogenesis in the mouse.
Topics: Animals; Aspirin; Body Temperature; Bone and Bones; Congenital Abnormalities; Female; Fever; Gestati | 1998 |
Teratogenicity of therapeutic agents.
Topics: Abnormalities, Drug-Induced; Abnormalities, Radiation-Induced; Abortion, Induced; Anesthetics; Anima | 1979 |
Congenital malformations in nonhuman primates: spontaneous and experimentally induced.
Topics: Abnormalities, Drug-Induced; Aminopterin; Animals; Aspirin; Congenital Abnormalities; Female; Haplor | 1967 |
Alleviation of the leg abnormality in zinc-deficient chicks by histamine and by various anti-arthritic agents.
Topics: Amine Oxidase (Copper-Containing); Animals; Arthritis; Aspirin; Chickens; Congenital Abnormalities; | 1968 |
Sporadic malformations in laboratory animals and their influence on drug testing.
Topics: Abnormalities, Drug-Induced; Animals; Animals, Laboratory; Aspirin; Bone and Bones; Congenital Abnor | 1972 |
Experimental teratology and pediatrics.
Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Congenital Abnormalities; Female; Fetal Diseases; Mam | 1970 |